Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.73 |
| ▸ | RAB9A | P51151 | 4/20 | 0.73 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.72 |
| ▸ | CHRNA5 | P30532 | 3/20 | 0.72 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | GRM5 | P41594 | 9/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2035283 | 0.89 | CHRNB2 (0.72) | NPC1RAB9ACHRNB2CHRNA5CHRNA4 | |
| SCHEMBL2040629 | 0.86 | NPC1 (0.51) | NPC1RAB9ACHRNB2CHRNA5CHRNA4 | |
| SCHEMBL2036233 | 0.84 | CHRNB2 (0.72) | NPC1RAB9ACHRNB2CHRNA5CHRNA4 | |
| SCHEMBL2037812 | 0.84 | CHRNB2 (0.72) | NPC1RAB9ACHRNB2CHRNA5CHRNA4 | |
| SCHEMBL2035021 | 0.84 | CHRNB2 (0.72) | NPC1RAB9ACHRNB2CHRNA5CHRNA4 | |
| SCHEMBL2037687 | 0.82 | CHRNB2 (0.68) | NPC1RAB9ACHRNB2CHRNA5CHRNA4 | |
| SCHEMBL2035922 | 0.81 | NPC1 (0.48) | NPC1RAB9ACHRNB2CHRNA5CHRNA4 | |
| SCHEMBL2037580 | 0.80 | NPC1 (0.46) | NPC1RAB9ACHRNB2CHRNA5CHRNA4 | |
| SCHEMBL2039501 | 0.79 | NPC1 (0.46) | NPC1RAB9ACHRNB2CHRNA5CHRNA4 | |
| SCHEMBL2120823 | 0.79 | CHRNB2 (0.61) | NPC1RAB9ACHRNB2CHRNA5CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309792-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2012-12-06 | — | — | US | claimed |
| EP-2513087-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MOUDLATORS | NeuroSearch A/S (DK) | 2012-10-24 | — | — | EP | claimed |
| WO-2011073297-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MOUDLATORS | NEUROSEARCH A/S (DK) | 2011-06-23 | — | — | WO | claimed |
| US-20120309792-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2012-12-06 | — | — | US | disclosed |
| EP-2513087-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MOUDLATORS | NeuroSearch A/S (DK) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011073297-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MOUDLATORS | NEUROSEARCH A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309792-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | CHRNA5, CHRNA7, CHRNA3 | NPC1 3279/4885RAB9A 2992/4885CHRNB2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.